MiniMed Group, Inc.

MiniMed Group, Inc. is a medical technology company dedicated to developing, manufacturing, and marketing advanced equipment for diabetes management. Headquartered in Northridge, California, the company's mission is to alleviate the burden of diabetes through technology, striving to make every day better for individuals living with the condition by introducing stability and predictability into their care.

The company offers a comprehensive portfolio of diabetes management solutions, positioning itself as a full-stack insulin delivery provider. Key offerings include insulin delivery devices such as insulin pumps and smart insulin pens, continuous glucose monitors (CGMs), and related consumables, supplies, software, and services. Its platform features Automated Insulin Delivery (AID) systems, notably the MiniMed™ 780G system, and Smart Multiple Daily Injection (MDI) systems like InPen, Simplera, and Guardian 4, all designed to create an integrated diabetes ecosystem.

MiniMed recently became an independent, publicly traded company, having spun off from Medtronic plc in March 2026, with its shares trading on NASDAQ under the ticker MMED. While Medtronic initially retained approximately 90% ownership post-IPO, MiniMed operates as a standalone entity led by CEO Que Dallara. The company has been actively launching new products, including the MiniMed Go™ Smart MDI system and the MiniMed Flex™ system, and emphasizes its unique position as the only major player offering a fully closed, native ecosystem for diabetes management, integrating its hardware with proprietary software like CareLink.